Glioblastoma Treatment: State-of-the-Art and Future Perspectives.

Int J Mol Sci · 2022 · PMC9267036 · PMID 35806212

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may not be significantno p-value reported

The poor results in this trial may be attributed to the selection of a single target antigen, because even though EGFRvIII is present in approximately 30% of GB tumors, only a few cells within the tumor express the antigen, and the number of targeted cells may not be significant for the whole destruction of the tumor [ 33 , 51 , 56 , 61 , 62 ].

also in 2,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.